Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katja Sockel

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
Blood|June 6, 2022
Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysisMarie Robin, Liesbeth C de Wreede, Eric Padron, et al.
Blood|June 17, 2021
CHIP and hips: clonal hematopoiesis is common in patients undergoing hip arthroplasty and is associated with autoimmune diseaseJudith S Hecker, Luise Hartmann, Jennifer Rivière, et al.
The Lancet. Oncology|November 17, 2018
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trialUwe Platzbecker, Jan Moritz Middeke, Katja Sockel, et al.
Bone Marrow Transplantation|January 10, 2024
Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMTMitja Nabergoj, Diderik-Jan Eikema, Linda Koster, et al.
American Journal of Hematology|May 29, 2026
Trends in Transplantation for Myelodysplastic Syndrome Patients Across Recent Decades: A Registry-Based Study on Behalf of the Chronic Malignancies Working of the EBMTMarie Robin, Luuk Gras, Linda Koster, et al.
Leukemia|September 7, 2022
Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCOAnne Sophie Kubasch, Aristoteles Giagounidis, Georgia Metzgeroth, et al.
Bone Marrow Transplantation|December 24, 2025
A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on 'real world' experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithmAlexandros Rampotas, Jose Maria Aspa-Cilleruelo, Linda Koster, et al.
American Journal of Hematology|November 27, 2023
Outcomes of CMML patients undergoing allo-HCT are significantly worse compared to MDS-a study of the CMWP of the EBMTAlicia Rovó, Luuk Gras, Brian Piepenbroek, et al.
Blood|March 27, 2025
Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosisJuan Carlos Hernandez-Boluda, Adrian Mosquera Orgueira, Luuk Gras, et al.
American Journal of Hematology|February 22, 2024
Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMTNicola Polverelli, Edouard F Bonneville, Liesbeth C de Wreede, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
Blood|June 6, 2022
Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysisMarie Robin, Liesbeth C de Wreede, Eric Padron, et al.
Blood|June 17, 2021
CHIP and hips: clonal hematopoiesis is common in patients undergoing hip arthroplasty and is associated with autoimmune diseaseJudith S Hecker, Luise Hartmann, Jennifer Rivière, et al.
The Lancet. Oncology|November 17, 2018
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trialUwe Platzbecker, Jan Moritz Middeke, Katja Sockel, et al.
Bone Marrow Transplantation|January 10, 2024
Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMTMitja Nabergoj, Diderik-Jan Eikema, Linda Koster, et al.
American Journal of Hematology|May 29, 2026
Trends in Transplantation for Myelodysplastic Syndrome Patients Across Recent Decades: A Registry-Based Study on Behalf of the Chronic Malignancies Working of the EBMTMarie Robin, Luuk Gras, Linda Koster, et al.
Leukemia|September 7, 2022
Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCOAnne Sophie Kubasch, Aristoteles Giagounidis, Georgia Metzgeroth, et al.
Bone Marrow Transplantation|December 24, 2025
A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on 'real world' experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithmAlexandros Rampotas, Jose Maria Aspa-Cilleruelo, Linda Koster, et al.
American Journal of Hematology|November 27, 2023
Outcomes of CMML patients undergoing allo-HCT are significantly worse compared to MDS-a study of the CMWP of the EBMTAlicia Rovó, Luuk Gras, Brian Piepenbroek, et al.
Blood|March 27, 2025
Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosisJuan Carlos Hernandez-Boluda, Adrian Mosquera Orgueira, Luuk Gras, et al.
American Journal of Hematology|February 22, 2024
Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMTNicola Polverelli, Edouard F Bonneville, Liesbeth C de Wreede, et al.
Pageof 10